| Ad Title: |
Central Retinal Vein Occlusion |
| Study Title: |
FVF4166g: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion |
| Protocol Number: |
062007-017 |
| Department(s) involved in the Study: |
Ophthalmology
|
| Purpose of the Study: |
The study investigators will assess the efficacy of intravitreal injections of Lucentis administered monthly for 6 months in the improvement of visual acuity as measured by the mean change in best corrected visual acuity (BCVA) at 6 months compared with baseline in patients with CRVO. They will also evaluate the safety and tolerability of intravitreal injections of Lucentis administered monthly for 6 months, followed by a 6-month observation period with protocol-specified retreatment criteria. |
| Participant Eligibility: |
Please contact the study coordinator for more information regarding the study eligibility criteria. |
| Disease/Condition Under Study: |
Retinal ocular disease
Central Retinal Vein Occlusion (CRVO) |
| Cancer Related Study: |
No
|
| Study Drug(s): |
LUCENTIS (Ranibizumab injection)
|
| Study Device(s): |
|
| Study Doctor: |
Dr. Yuguang He |
| Location of Study: |
|
Sites
|
Recruiting at this Site
|
|
Aston Ambulatory Care Center
|
Yes
|
|
UT Southwestern Medical Center
|
Yes
|
|
| Contact Phone: |
214-645-2015 |
| Email: |
Jessica.Janecek-Griffin@UTSouthwestern.edu |
| Other Information: |
|
| Website Keywords: |
Ophthalmology
|
| Medical Keywords: |
blinding eye condition, CRVO, ocular, ophthalmic, ophthalmology, retinal disease
|
